Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 3
Submit an article Journal homepage
72
Views
33
CrossRef citations to date
0
Altmetric
Review

Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy

Mark R Schleiss Pediatrics and Molecular and Developmental Biology, Children#x2019s Hospital Research Foundation, Cincinnati, Ohio 45229, USA. [email protected]
&
Michael A McVoy Pediatrics, Virginia Commonwealth University, Richmond,Virginia, USA
Pages 389-403 | Published online: 10 Jan 2014

References

  • Britt WJ, Alford CA. Cytomegalovirus. In: Fields Virology . Fields BN, Knipe DM, 3rd Edition Howley PM (Eds). Lippincott—Raven, New York, NY, USA, 2493–2523 (1996).
  • Ribbert H. Uber protozoenartigen Zellen in der Nireeines syphilitischen Neugeboren und in der Parotis von Kindern. Zentralbl Allg. Pathol15, 945–948 (1904).
  • Goodpasture EQ, Talbot FB. Concerning the nature of 'protozoan-like' cells in certain lesions of infancy. Am. J. Dis. Child. 21,415–425 (1921).
  • Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc. Soc. Exp. Biol Med 92,424–430 (1956).
  • Rowe WP, Hartley JW, Waterman S, et al. Cytopathogenic agent resembling salivary gland virus recovered from tissue cultures of human adenoids. Proc. Soc. Exp. Biol. Med. 92,418–424 (1956).
  • Weller TH, Macauley JC, Craig JM, et al. Isolation of intranudear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc. Soc. Exp. Biol. Med. 94,4–12 (1956).
  • Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J. Med. 285(4), 203–214. II. N Engl J. Med. 285(5), 267–274 (1971).
  • ••A landmark article outlining the widerange of clinical manifestations associated with cytomegalovirus infection.
  • Mocarski ES, Courcelle CT Cytomegalovirus and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott—Raven, New York, NY, USA, 2629–2673 (2001).
  • Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr. Infect. Dis. J. 18,313–325 (1999).
  • ••Outstanding overview of the rationale fora cytomegalovirus vaccine, potential strategies for vaccination and the types of vaccines currently in development.
  • Adler SP Current prospects for immunization against cytomegaloviral disease. Infect. Agents Dis. 5,29–35 (1996).
  • Pass RF. Immunization strategy for prevention of congenital cytomegalovirus infection. Infect. Agents Dis. 5,240–244 (1996).
  • Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbial 8,410–418 (2000).
  • Mocarski ES. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbial 10, 332–339 (2000).
  • •Excellent overview of a remarkable aspect of cytomegalovirus biology, that of viral immune evasion genes and functional mechanisms.
  • Saederup N, Mocarski ES. Fatal attraction: cytomegalovirus-encoded chemokine homologs. Curr. Top. Microbial Immunol 269,235–256 (2002).
  • Vink C, Smit MJ, Leurs R, Bruggeman CA. The role of cytomegalovirus-encoded homologs of G-protein coupled receptors and chemokines in manipulation of and evasion from the immune system. J. Clin. Viral 23,43–55 (2001).
  • Demmler GJ. Congenital cytomegalovirus infection and disease. Adv. Pediatr. Infect. Dis. 11,135–162 (1996).
  • •• Detailed and comprehensive overview of congenital cytomegalovirus infection.
  • Bale JF, Miner L, Petheram SJ. Congenital cytomegalovirus infection. Curr. Treat.Options Neural 4(3), 225–230 (2002).
  • Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 66(5), 758–762 (1980).
  • Noyola DE, Demmler GJ, Nelson CT, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J. Pediatr. 138(3), 325–331 (2001).
  • Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?j Pediatr. 135(1), 60–64 (1999).
  • •Valuable contribution to the literature outlining scope of the problem of congenital cytomegalovirus-associated hearing loss.
  • Dahle AJ, Fowler KB, Wright JD, et al Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J. Am. Acad Audial 11, 283–290 (2000).
  • •Novel insights into the natural history and hearing prognosis for infants with congenital cytomegalovirus infection.
  • Fowler KB, Stagno S, Pass RF, et al The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J. Med 326,663–667(1992).
  • ••Landmark paper examining the role ofmaternal immunity hi congenital cytomegalovirus infection and disease.
  • Boppana SB, Rivera LB, Fowler KB, et al Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J. Med 344,1366–1371 (2001).
  • •Another landmark paper examining the roleof maternal immunity in congenital cytomegalovirus infection and disease.
  • Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand. J. Infect. Dis. 31,443–457 (1999).
  • Boppana SB, Fowler KB, Britt WJ, et al Symptomatic congenital cytomegalovirus infection in infants born to mothers with pre-existing immunity to cytomegalovirus. Pediatrics 104,55–60 (1999).
  • Adler SP Neonatal cytomegalovirus infections due to blood. Crit. Rev. Clin. Lab. Sci. 23, 1–14 (1986).
  • Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr 98, 281–287 (1981).
  • Ballard RA, Drew WI., Hufnagle KG, Riedel PA. Acquired cytomegalovirus infection in preterm infants. Am. J. Dis. Child 133, 482–485 (1979).
  • Dworsky M, Yow M, Stagno S, et al Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics 72, 295–299 (1983).
  • Maschmann J, Hamprecht K, Dietz K, et al. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin. Infect. Dis. 33, 1998–2003 (2001).
  • •Outstanding clinical research identifying previously underappreciated morbidity in low birth-weight premature infants due to cytomegalovirus infections acquired via breast milk.
  • Yasuda A, Kimura H, Hayakawa M, et al. Evaluation of cytomegalovirus infections transmitted via breast milk in preterm infants with a real-time polymerase chain reaction assay. Pediatrics 111,1333–1336 (2003).
  • Azam AZ, Vial Y, Fawer CL, et al Prenatal diagnosis of congenital cytomegalovirus infection. Obstet. Gynecol 97,443–448 (2001).
  • Grangeot-Keros L, Simon B, Audibert F, Vial M. Should we routinely screen for cytomegalovirus antibody during pregnancy? intervirdogy 41,158–162 (1998).
  • Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J. Med 314, 1414–1418 (1986).
  • Adler SP Molecular epidemiology of cytomegalovirus: evidence for viral transmission to parents from children infected at a day-care center. Pediatr Infict. Dis. 5,315–318 (1986).
  • Revello MG, Gema G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus and newborn infant. Clin. Microbial Rev. 15,680–715 (2002).
  • ••Extremely valuable review of all aspects ofcytomegalovirus infection of maternal—placental—fetal unit: virology, pathogenesis, immunity, therapy and prognosis.
  • Lazzarotto T, Varani S, Guerra B, et al Prenatal indicators of congenital cytomegalovirus infection. J. Pediatr 137(1), 90–95 (2000).
  • Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect. Dis. J 15,240–246 (1996).
  • Wade JC, Hintz M, McGuffin R, et al. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am. J. Med. 73, 249–256 (1982).
  • Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infection. J. Clin. Viral. 16,25–40 (2000).
  • Schleiss MR Cytomegalovirus in immunocompromised persons. Curr Treat. Options Infect. Dis. 4,43–50 (2002).
  • Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin. Pediatr Infect. Dis. 13(1), 22–30 (2002).
  • Griffiths PD. The 2001 Garrod lecture. The treatment of cytomegalovirus infection. Antimicrob. Chemother 49(2), 243–253 (2002).
  • Sullivan V, Talarico CL, Stanat SC, et al A protein kinase homolog controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358, 162–164 (1992).
  • Littler E, Stuart AD, Chee MS. Human cytomegalovirus U1L97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analog ganciclovir. Nature 358,160–162 (1992).
  • Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbial Rev. 12, 286–297 (1999).
  • Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbial Rev. 11, 533–554 (1998).
  • Chou S, Lurain NS, Thompson KD, et al Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188(1), 32–39 (2003).
  • Chou S. Antiviral drug resistance in human cytomegalovirus. Tianspl Infect. Dis. 1(2), 105–114 (1999).
  • Neyts J, De Clercq E. Mycophenolate mofetil strongly potentiates the antiherpesvirus activity of acyclovir. Antiviral Res. 40(1–2), 53–56 (1998).
  • Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother 42(2), 216–222 (1998).
  • Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G KR)-944-hydroxy-2-(hydroxymethyllbutyflguanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob. Agents Chemother 42(12), 3285–3289 (1998).
  • Beadle JR, Hartline C, AMem KA, et al Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother 46(8), 2381–2386 (2002).
  • Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infections. J. Infect. Dis. 2004 (In Press).
  • Underwood MR, Harvey RJ, Stanat SC, et al Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Viral 72(1), 717–725 (1998).
  • Krosky PM, Underwood MR, Turk SR, et al Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: 1JL89 and 1JL56. J. Viral. 72(6), 4721–4728 (1998).
  • Visalli RJ, van Zeill M. DNA encapsidation as a target for antiherpesvirus drug therapy. Antiviral Res. 59(2), 73–87 (2003).
  • Biron KK, Harvey RJ, Chamberlain SC, et al Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother 46(8), 2365–2372 (2002).
  • Krosky PM, Baek MC, Coen DM. The human cytomegalovirus 1JL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Viral. 77(2), 905–914 (2003).
  • Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Viral 77(21), 11499–11506 (2003).
  • Evers DL, Komazin G, Shin D, Hwang DD, Townsend LB, Drach JC. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Res. 56(1), 61–72 (2002).
  • Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother 47(4), 1468–1471 (2003).
  • Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother 46(8), 2373–2380 (2002).
  • McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK. Inhibition of ganciclovir-susceptible and-resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab. Immunol 8(6), 1279–1281 (2001).
  • Chulay J, Biron K, Wang L, et al. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med. Biol. 458,129–134 (1999).
  • Lalezari JP, Aberg JA, Wang LH, et al Phase I dose escalation trial evaluating the pharmacokinetics, antihuman cytomegalovirus activity and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46(9), 2969–2976 (2002).
  • Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral antihuman cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47(4), 1334–1342 (2003).
  • Williams SL, Hartline CB, Kushner NIL, et al In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47(7), 2186–2192 (2003).
  • Buerger I, Reefschlaeger J, Bender W, et al A novel non-nucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56gene products. J. Viral. 75(19), 9077–9086 (2001).
  • Reefschlaeger J, Bender W, Hallenberger S, et al Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38–4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48(6), 757–767 (2001).
  • McSharry JJ, McDonough A, Olson B, et al Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695 and ganciclovir. Antimicrob. Agents Chemother. 45(10), 2925–2927 (2001).
  • Weber O, Bender W, Eckenberg P, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res. 49(3), 179–189 (2001).
  • Nagelschmitz J, Moeller JG, Stass H, et al. Safety, tolerability and pharmacokinetics of single oral doses of BAY 38–4766 — a novel, non-nucleosidic inhibitor of human cytomegalovirus replication in healthy male subjects. Proceedings of the 39th ICAAC CA, USA, 26–29 September (1999) (Abstract 945).
  • Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. biterviro/ogy 42(5–6), 412–418 (1999).
  • Plotkin SA, Stetler H. Treatment of congenital cytomegalic inclusion disease with antiviral agents. Antimicrob. Agents Chemother. 9,372–379 (1969).
  • Fan-Harvard P, Nahata NC, Brady MT. Ganciclovir — a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus pneumonia. J. Clin. Pharmacol. Ther. 14, 329–340 (1989).
  • Hocker J, Cook LN, Adams G, Rabalais G. Ganciclovir therapy of congenital cytomegalovirus pneumonia. Pediatr. Infect. Dis. 9,743–745 (1990).
  • Attard-Montalto SP, English MC, Stimmler L, Snodgrass GJ. Ganciclovir treatment of congenital cytomegalovirus infection: a report of two cases. Scand. J. Infect. Dis. 25(3), 385–288 (1993).
  • Vallejo JG, Englund JA, Garcia-Prats JA, Demmler GJ. Ganciclovir treatment of steroid-associated cytomegalovirus disease in a congenitally infected neonate. Pediatr. Infect. Dis. J. 13(3), 239–241 (1994).
  • Junker A, Matheson D, Tingle A, Thomas E. Immune responses after ganciclovir and immunoglobulin therapy of infants. Pediatr. Infect. Dis. J. 10,256–258 (1991).
  • Reigstad H, Bjerknes R, Markestad T, Myrmel H. Ganciclovir therapy of congenital cytomegalovirus disease. Acta Paediatr. 81(9), 707–708 (1992).
  • Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr. Infect. Dis. J. 22(6), 504–509 (2003).
  • Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J. Pediatr. 124(2), 318–322 (1994).
  • Crowley B. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection. J. Antimicrob. Chemother. 50(3), 435–436 (2002).
  • Nigro G, Krzysztofiak A, Bartmann U, et al. Ganciclovir therapy for cytomegalovirus-associated liver disease in immunocompetent or immunocompromised children. Arch Viral. 142(3), 573–580 (1997).
  • Fischler B, Casswall TH, Malmborg P, Nemeth A. Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis. J. Pediatr. Gastroenterol. Nutr. 34(2), 154–157 (2002).
  • Trang JM, Kidd L, Gruber W, et al. and the NIAID Collaborative Antiviral Study Group. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin. Pharmacol. Ther. 53,15–21 (1993).
  • Zhou XJ, Gruber W, Demmler G, et al. and the NIAID Collaborative Antiviral Study Group. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Antimicrob. Agents Chemother. 40,2202–2205 (1996).
  • Whitley RJ, Cloud G, Gruber W, et al. and the NIAID Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. J. Infect. Dis. 175,1080–1086 (1997).
  • Kimberlin DW, Lin CY, Sanchez PJ, et al Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143(1), 16–25 (2003).
  • ••An extraordinary accomplishment and a testimony to perseverance: results of a multicenter, controlled trial of ganciclovir in affected newborns reveals that antiviral therapy is of value in protecting against sensorineural hearing loss.
  • Zaknun D, Zangerle R, Kapelari K, et al. Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Pediatr. Infect. Dis. J. 16(8), 807–811 (1997).
  • Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transpl. 27(6), 621–626 (2001).
  • Blackman S, Lurain N, Filopovich A, et al. Compartmentalization and multi-drug resistance of CMV in a patient with autosomal-recessive SCID. Soc. Pediatr. Path. (2003) (Abstract 7).
  • Snydman DR, Werner BG, Meissner HC, et al. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr. Infect. Dis. J. 14(1), 34–40 (1995).
  • Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus Type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl. J. Med. 331(18), 1173–1180 (1994).
  • Henderson GI, Hu ZQ, Yang Y, et al. Ganciclovir transfer by human placenta and its effects on rat fetal cells. Am. J. Med. Sci. 306(3), 151–156 (1993).
  • Gilstrap LC, Bawdon RE, Roberts SW, Sobhi S. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Am. J. Obstet. Gynecol. 170(4), 967–972 (1994).
  • Kimberlin DW. New antiviral therapeutic agents. Semin. Pediatr. Infect. Dis. 12, 224–234 (2001).
  • Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 67(5), 758–759 (1999).
  • Laifer SA, Ehrlich GD, Huff DS, et al. Congenital cytomegalovirus infection in offspring of liver transplant recipients. Clin. Infect. Dis. 20(1), 52–55 (1995).
  • Miguelez M, Gonzalez A, Perez F. Severe cytomegalovirus hepatitis in a pregnant woman treated with ganciclovir. Scand. J. Infect. Dis. 30(3), 304–305 (1998).
  • Revello MG, Percivalle E, BaManti F, et al Prenatal treatment of congenital human cytomegalovirus infection by fetal intravascular administration of ganciclovir. Clin. Diagn. Viral 1, 61–67 (1993).
  • Revello MG, Gema G. Diagnosis of implications of cytomegalovirus infection in pregnancy. Fel. Matern. Med Rev. 11, 117–134 (1999).
  • Brady RC, Schleiss MR, Witte D, et al Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease. Pediatr Infict. Dis. J. 21(8), 796–797 (2002).
  • Revello MG, Zavattoni M, Furione M, et al Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin. Microbial 37(10), 3350–3352 (1999).
  • Stratton KR, Durch JS, Lawrence RS (Eds). Vaccines fir the 21st Century: a Tool for Decisionmaking. Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, DC, USA (1999).
  • •The Institute of Medicine has identified cytomegalovirus vaccines as the highest-level area for new vaccine development in the new millennium. The costs to society associated with congenital cytomegalovirus infection am staggering. Vaccines are sorely needed.

Website

  • Collaborative Antiviral Study Group http://www.casg.uab.edu Accessed May 2004

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.